The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 10, 2009, Pages 3806-3811

  Coffelt, Seth B ^a   Marini, Frank C ^b   Watson, Keri ^b   Zwezdaryk, Kevin J ^c   Dembinski, Jennifer L ^b   LaMarca, Heather L ^d   Tomchuck, Suzanne L ^c   Zu Bentrup, Kerstin Honer ^c   Danka, Elizabeth S ^c   Henkle, Sarah L ^c   Scandurro, Aline B ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF TEXAS   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

FPRL1; hCAP 18; Mesenchymal stem cell; Ovarian cancer; Tumor engraftment

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; GELATINASE A; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MATRIGEL; RANTES; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MESENCHYMAL STEM CELL; METASTASIS; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; STROMA CELL; XENOGRAFT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOTACTIC FACTORS; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MESODERM; MICE; MODELS, BIOLOGICAL; MULTIPOTENT STEM CELLS; NEUTRALIZATION TESTS; OVARIAN NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; STROMAL CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 62649126972     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0900244106     Document Type: Article

References (37)

1. Coffelt SB, et al. (2008) Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer 122:1030-1039.
2. Heilborn JD, et al. (2005) Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer 114:713-719.
3. von Haussen J, et al. (2008) The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer 59:12-23.
4. Agerberth B, et al. (1995) FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA 92:195-199.
5. Larrick JW, et al. (1995) Human CAP18: A novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 63:1291-1297.
6. Larrick JW, Hirata M, Zhong J, Wright SC (1995) Anti-microbial activity of human CAP18 peptides. Immunotechnology 1:65-72.
7. Koczulla R, et al. (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111:1665-1672.
8. Shaykhiev R, et al. (2005) Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol 289:L842-L848.
9. Heilborn JD, et al. (2003) The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 120:379-389.
10. Cowland JB, Johnsen, AH, Borregaard, N (1995) hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett 368:173-176.
11. Sorensen OE, et al. (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97:3951-3959.
12. Sorensen OE, et al. (2003) Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: A novel mechanism of generating antimicrobial peptides in vagina. J Biol Chem 278:28540-28546.
13. Yang D, et al. (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192:1069-1074.
14. Agerberth B, et al. (2000) The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96:3086-3093.
15. Studeny M, et al. (2004) Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:1593-1603.
16. Studeny M, et al. (2002) Bone marrow-derived mesenchymal stem cells as vehicles for intereron-beta delivery into tumors. Cancer Res 62:3603-3608.
17. Nakamizo A, et al. (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307-3318.
18. Klopp AH, et al. (2007) Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 67:11687-11695.
19. Karnoub AE, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-563.
20. Dwyer RM, et al. (2007) Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 13:5020-5027.
21. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L (2006) Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 5:755-766.
22. Stoff-Khalili MA, et al. (2007) Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 105:157-167.
23. Khakoo AY, et al. (2006) Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 203:1235-1247.
24. Ramasamy R, et al. (2007) Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth. Leukemia 21:304-310.
25. Djouad F, et al. (2003)Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102:3837-3844.
26. Tomchuck SL, et al. (2008) Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26:99-107.
27. Zwezdaryk KJ, et al. (2007) Erythropoietin, a hypoxia-regulated factor, elicits a proangiogenic program in human mesenchymal stem cells. Exp Hematol 35:640-652.
28. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F (2008) Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15:730-738.
29. Viswanathan A, Painter RG, Lanson NA, Jr, Wang, G (2007) Functional expression of N-formyl peptide receptors in human bone marrow-derived mesenchymal stem cells. Stem Cells 25:1263-1269.
30. Uccelli A, Moretta, L, Pistoia, V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol, in press.
31. Coffelt SB, Scandurro, AB (2008) Tumors sound the alarmin(s). Cancer Res 68:6482-6485.
32. Au P, Tam J, Fukumura D, Jain RK (2008) Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 111:4551-4558.
33. Covas DT, et al. (2008) Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 36:642-654.
34. Mishra PJ, et al. (2008) Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68:4331-4339.
35. Beyth S, et al. (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105:2214-2219.
36. Ren G, et al. (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2:141-150.
37. Yotnda P, et al. (2004) Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther 15:1229-1242.